TP53 and mantle cell lymphoma: The promising efficacy of combination targeted therapies in the front-line setting is particularly appealing for patients for whom suboptimal outcomes with cytotoxic chemotherapy are expected, such as TP53 abnormal MCL or blastoid/pleomorphic subtypes.